272 related articles for article (PubMed ID: 32852651)
21. Severe hypertriglyceridemia: Existing and emerging therapies.
Malick WA; Do R; Rosenson RS
Pharmacol Ther; 2023 Nov; 251():108544. PubMed ID: 37848164
[TBL] [Abstract][Full Text] [Related]
22. Familial chylomicronemia syndrome due to a heterozygous deletion of the chromosome 8 treated with the apoCIII inhibitor volanesorsen: A case report.
Tünnemann-Tarr A; Scharnagl H; Katzmann JL; Stürzebecher P; Laufs U
Medicine (Baltimore); 2021 Oct; 100(42):e27573. PubMed ID: 34678899
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of efficacy and safety of antisense inhibition of apolipoprotein C-III with volanesorsen in patients with severe hypertriglyceridemia.
D'Erasmo L; Gallo A; Di Costanzo A; Bruckert E; Arca M
Expert Opin Pharmacother; 2020 Oct; 21(14):1675-1684. PubMed ID: 32646313
[TBL] [Abstract][Full Text] [Related]
24. Analyses of familial chylomicronemia syndrome in Pereira, Colombia 2010-2020: a cross-sectional study.
Rodriguez FH; Estrada JM; Quintero HMA; Nogueira JP; Porras-Hurtado GL
Lipids Health Dis; 2023 Mar; 22(1):43. PubMed ID: 36978188
[TBL] [Abstract][Full Text] [Related]
25. ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.
Rocha NA; East C; Zhang J; McCullough PA
Curr Atheroscler Rep; 2017 Nov; 19(12):62. PubMed ID: 29124482
[TBL] [Abstract][Full Text] [Related]
26. Targeting APOC3 in the familial chylomicronemia syndrome.
Gaudet D; Brisson D; Tremblay K; Alexander VJ; Singleton W; Hughes SG; Geary RS; Baker BF; Graham MJ; Crooke RM; Witztum JL
N Engl J Med; 2014 Dec; 371(23):2200-6. PubMed ID: 25470695
[TBL] [Abstract][Full Text] [Related]
27. Management of a pregnant patient with chylomicronemia from a novel mutation in GPIHBP1: a case report.
Lin MH; Tian XH; Hao XL; Fei H; Yin JL; Yan DD; Li T
BMC Pregnancy Childbirth; 2020 May; 20(1):272. PubMed ID: 32375710
[TBL] [Abstract][Full Text] [Related]
28. Role of lipoprotein lipase activity measurement in the diagnosis of familial chylomicronemia syndrome.
Rioja J; Ariza MJ; Benítez-Toledo MJ; Espíldora-Hernández J; Coca-Prieto I; Arrobas-Velilla T; Camacho A; Olivecrona G; Sánchez-Chaparro MÁ; Valdivielso P
J Clin Lipidol; 2023; 17(2):272-280. PubMed ID: 36813655
[TBL] [Abstract][Full Text] [Related]
29. Familial chylomicronemia syndrome: A rare but devastating autosomal recessive disorder characterized by refractory hypertriglyceridemia and recurrent pancreatitis.
Chyzhyk V; Brown AS
Trends Cardiovasc Med; 2020 Feb; 30(2):80-85. PubMed ID: 31003756
[TBL] [Abstract][Full Text] [Related]
30. Challenges in familial chylomicronemia syndrome diagnosis and management across Latin American countries: An expert panel discussion.
Santos RD; Lorenzatti A; Corral P; Nogueira JP; Cafferata AM; Aimone D; Lourenço CM; Izar MC; Lima JG; Lottenberg AM; Alonso R; Garay K; Morales AR; Vargas-Uricoechea H; Peña CAC; Roman-González A
J Clin Lipidol; 2021; 15(5):620-624. PubMed ID: 34920815
[TBL] [Abstract][Full Text] [Related]
31. Apolipoprotein C-III, familial chylomicronemia syndrome, and olezarsen.
Valdivielso P; Coca Prieto I
Med; 2024 Jun; 5(6):493-494. PubMed ID: 38878767
[TBL] [Abstract][Full Text] [Related]
32. The Chylomicronemia Syndrome Is Most Often Multifactorial: A Narrative Review of Causes and Treatment.
Chait A; Eckel RH
Ann Intern Med; 2019 May; 170(9):626-634. PubMed ID: 31035285
[TBL] [Abstract][Full Text] [Related]
33. Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome.
Witztum JL; Gaudet D; Freedman SD; Alexander VJ; Digenio A; Williams KR; Yang Q; Hughes SG; Geary RS; Arca M; Stroes ESG; Bergeron J; Soran H; Civeira F; Hemphill L; Tsimikas S; Blom DJ; O'Dea L; Bruckert E
N Engl J Med; 2019 Aug; 381(6):531-542. PubMed ID: 31390500
[TBL] [Abstract][Full Text] [Related]
34. Clinical and genetic features of 3 patients with familial chylomicronemia due to mutations in GPIHBP1 gene.
Rabacchi C; D'Addato S; Palmisano S; Lucchi T; Bertolini S; Calandra S; Tarugi P
J Clin Lipidol; 2016; 10(4):915-921.e4. PubMed ID: 27578123
[TBL] [Abstract][Full Text] [Related]
35. The role of antisense oligonucleotide therapy against apolipoprotein-CIII in hypertriglyceridemia.
Gouni-Berthold I
Atheroscler Suppl; 2017 Nov; 30():19-27. PubMed ID: 29096837
[TBL] [Abstract][Full Text] [Related]
36. A novel mutation in GPIHBP1 causes familial chylomicronemia syndrome.
Paquette M; Hegele RA; Paré G; Baass A
J Clin Lipidol; 2018; 12(2):506-510. PubMed ID: 29452893
[TBL] [Abstract][Full Text] [Related]
37. Familial chylomicronemia syndrome and response to medium-chain triglyceride therapy in an infant with novel mutations in GPIHBP1.
Ahmad Z; Wilson DP
J Clin Lipidol; 2014; 8(6):635-639. PubMed ID: 25499947
[TBL] [Abstract][Full Text] [Related]
38. Lipoprotein abnormalities in compound heterozygous lipoprotein lipase deficiency after treatment with a low-fat diet and orlistat.
Blackett P; Tryggestad J; Krishnan S; Li S; Xu W; Alaupovic P; Quiroga C; Copeland K
J Clin Lipidol; 2013; 7(2):132-9. PubMed ID: 23415432
[TBL] [Abstract][Full Text] [Related]
39. The burden of familial chylomicronemia syndrome: Results from the global IN-FOCUS study.
Davidson M; Stevenson M; Hsieh A; Ahmad Z; Roeters van Lennep J; Crowson C; Witztum JL
J Clin Lipidol; 2018; 12(4):898-907.e2. PubMed ID: 29784572
[TBL] [Abstract][Full Text] [Related]
40. Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial.
Witztum JL; Gaudet D; Arca M; Jones A; Soran H; Gouni-Berthold I; Stroes ESG; Alexander VJ; Jones R; Watts L; Xia S; Tsimikas S
J Clin Lipidol; 2023; 17(3):342-355. PubMed ID: 37100699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
